VAY736 1ml PFS + VAY736 2 ml PFS + VAY736 2ml AI
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögrens Disease
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Trial Timeline
Jul 2, 2024 → Jan 4, 2029
NCT ID
NCT06293365About VAY736 1ml PFS + VAY736 2 ml PFS + VAY736 2ml AI
VAY736 1ml PFS + VAY736 2 ml PFS + VAY736 2ml AI is a phase 2 stage product being developed by Novartis for Sjögrens Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06293365. Target conditions include Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06293365 | Phase 2 | Active |
Competing Products
1 competing product in Sjögrens Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abiprubart + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |